JKJoo Young Kim

Joo Young Kim

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Joo Young Kim has a total of 137 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Dissolving Microneedle for Maintaining the Integrity of HPV Virus‐Like Particles Enabling Durable Sterile Protection Across Various Mucosal Tissues

    by Hyemi Kim, Inhyuk Hwang, Juhee Seo, Chaiwon Kim, In‐Jeong Choi, Miran Kang, Min‐Seok Rha, Youngjae Hong, Jooyoung Kim, Seung‐Ki Baek, et al.

    Human papillomavirus (HPV) vaccines have substantially reduced cervical cancer and other HPV‐related diseases in high‐income countries, with male vaccination addressing transmission as well as head and neck cancers. However, in low‐ and middle‐income countries, widespread vaccination efforts are hindered by considerable costs, insufficient medical staff, and challenges in maintaining vaccine stability. Conventional microneedle vaccine production often compromises the structural integrity of virus‐like particles (VLPs), thereby reducing their effectiveness. To address this challenge, a dissolving microneedle platform is developed that preserves VLP stability for over six months. Administration of this vaccine platform to buccal tissue enables effective antigen delivery, inducing T follicular helper (Tfh) cell differentiation, germinal center formation, and the production of high‐titer neutralizing antibodies. Buccal application also conferred sterilizing immunity in both buccal and vaginal tissues. Moreover, the vaccine induced durable immune memory, with memory B cells and plasma cells persisting in buccal tissue and bone marrow for six months. This innovation addresses critical barriers in resource‐limited regions by enhancing VLP stability and accessibility. Furthermore, the platform's applicability extends to other vaccines requiring structural integrity for efficacy, representing a transformative approach to global immunization efforts.


  • Open Access

    Sublingual Immunization With an RSV G Glycoprotein Fragment Primes IL-17-Mediated Immunopathology Upon Respiratory Syncytial Virus Infection

    by In Su Cheon, Joo Young Kim, Youngjoo Choi, Byoung-Shik Shim, Jung-Ah Choi, Dae-Im Jung, Jae-Ouk Kim, Thomas J. Braciale, Hyewon Youn, Man Ki Song, et al.

    Respiratory syncytial virus (RSV) is the leading cause of serious respiratory tract disease but there is no licensed RSV vaccine. Immunopathological mechanisms have long been suspected as operating in the development of severe RSV disease and have hampered the development of safe and effective vaccines. Here, we show that unlike intranasal immunization, sublingual immunization with RSV glycoprotein fragment containing the central conserved region (Gcf) primes the host for severe disease upon RSV challenge. This increased pathology does not require replication by the challenge virus and is associated with massive infiltration of inflammatory cells, extensive cell death, and excessive mucus production in the airway and lungs. This exacerbated RSV disease primed by sublingual Gcf immunization is distinct from the immunopathology by G-expressing vaccinia virus or formalin-inactivated RSV, and preceded by prominent IL-17 production. IL-17 deficiency abolished the enhanced disease. Our results suggest a novel mechanism of RSV vaccine-induced immunopathology by IL-17, and highlights the importance of vaccination site.


  • Open Access

    Combined Effect of Secondhand Smoking and Alcohol Drinking on Risk of Persistent Human Papillomavirus Infection

    by Sang-Soo Seo, Hea Young Oh, Mi Kyung Kim, Dong Ock Lee, Youn Kyung Chung, Joo-Young Kim, Chan Wha Lee

    Tobacco smoking is established as a cofactor of human papillomavirus (HPV) for cervical cancer risk. However, the role of secondhand smoking in cervical carcinogenesis is controversial. We aimed to assess the association between secondhand smoking and high risk- (HR-) HPV persistence, a pivotal event in development of cervical cancer. In total, 9,846 women who underwent health-screening examinations from 2002 to 2011 at the National Cancer Center, Korea, were included. Secondhand smoking was defined as being exposed to secondhand smoke at home or in the workplace. Multivariate logistic regression analysis was used to estimate the odds ratios (OR) and 95% confidence intervals (CIs) for risks of HR-HPV infection at baseline (N, 9,846, negative vs. positive), 1-year persistence (n, 1,237, 1-year negative vs. 1-year persistence), and 2-year persistence (n, 481, 2-year negative vs. 2-year persistence). Active smoking, secondhand smoking, and secondhand smoking in nonactive smokers had no association with these risks. Among alcohol drinkers, secondhand smoking in nonactive smokers had higher risks of HR-HPV infection at baseline (OR = 1.25, 95% CI = 1.05–1.48, p for multiplicative interaction = 0.003), 1-year persistence (1.75, 1.14–2.68, 0.004), and 2-year persistence (2.96, 1.42–6.15, 0.006), when compared to HR-HPV negative, 1-year negative, and 2-year negative categories, respectively. However, among nonalcohol drinkers, there was no association between smoking or secondhand smoking status and these risks. These findings suggest that women exposed to secondhand smoking at home or in the workplace might be at high risk of HR-HPV persistence when it is combined with alcohol drinking, even though neither active smoking nor secondhand smoking independently affects the risk.


  • Involved-field radiation therapy for recurrent ovarian cancer: Results of a multi-institutional prospective phase II trial

    by Jee Suk Chang, Sang Wun Kim, Yeon-Joo Kim, Joo-Young Kim, Sang-Yoon Park, Jin Hee Kim, Tae-Kyu Jang, Yong Bae Kim


  • Open Access

    The effects of combined aerobic and resistance training on inflammatory markers in obese men

    by Chan-Ho Jin, Hyun-Seung Rhyu, Joo Young Kim

    It is important to treat obesity and the related noncommunicable diseases. The main objective of this study is the effect of different training types on inflammatory and immune markers in obesity. Seventeen obese men with body mass index (BMI)≥26 kg/m2 were randomly divided into two groups: aerobic training group (AT; n=9) and combined aerobic and resistance training group (CT; n=8). Body composition (weight, BMI, %body fat), factors of physical performance (one-repetition maximum [1RM], maximal oxygen uptake [VO2max]), inflammatory markers (interleukin-6, tumor necrosis factor-alpha [TNF-α]), immune markers (leukocyte, natural killer cell) were analyzed before and after 8-week training. Body composition (weight, BMI, and %body fat) was significantly reduced after training in both the AT and CT groups (P2max of all training groups was increased and 1RM of CT group was partially improved. In particular, the inflammatory marker, TNF-α was significantly reduced (P<0.05) and the change was correlated with %body fat in the posttraining CT group. In this study, we found that combined training for 8 weeks improved physical fitness, body composition, and inflammation. It is suggested that restoring obesity through combined training of aerobic and resistance exercise is related to changes in serum TNF-α levels.


  • Open Access

    Pan-Influenza A Protection by Prime–Boost Vaccination with Cold-Adapted Live-Attenuated Influenza Vaccine in a Mouse Model

    by Yo Han Jang, Joo Young Kim, Young Ho Byun, Ahyun Son, Jeong-Yoon Lee, Yoon Jae Lee, Jun Chang, Baik Lin Seong

    Influenza virus infections continually pose a major public health threat with seasonal epidemics and sporadic pandemics worldwide. While currently licensed influenza vaccines provide only strain-specific protection, antigenic drift and shift occasionally render the viruses resistant to the host immune responses, which highlight the need for a vaccine that provides broad protection against multiple subtypes. In this study, we suggest a vaccination strategy using cold-adapted, live attenuated influenza vaccines (CAIVs) to provide a broad, potent, and safe cross-protection covering antigenically distinct hemagglutinin (HA) groups 1 and 2 influenza viruses. Using a mouse model, we tested different prime–boost combinations of CAIVs for their ability to induce humoral and T-cell responses, and protective efficacy against H1 and H5 (HA group 1) as well as H3 and H7 (HA group 2) influenza viruses. Notably, even in the absence of antibody-mediated neutralizing activity or HA inhibitory activity in vitro, CAIVs provided a potent protection against heterologous and heterosubtypic lethal challenges in vivo. Heterologous combination of prime (H1)–boost (H5) vaccine strains showed the most potent cross-protection efficacy. In vivo depletion experiments demonstrated not only that T cells and natural killer cells contributed to the cross-protection, but also the involvement of antibody-dependent mechanisms for the cross-protection. Vaccination-induced antibodies did not enhance the infectivity of heterologous viruses, and prime vaccination did not interfere with neutralizing antibody generation by the boost vaccination, allaying vaccine safety concerns associated with heterogeneity between the vaccines and challenge strains. Our data show that CAIV-based strategy can serve as a simple but powerful option for developing a “truly” universal influenza vaccine providing pan-influenza A protection, which has not been achieved yet by other vaccine strategies. The promising results of potency, breadth, and safety demonstrated in the mouse model support further studies in higher animal models for clinical relevance.


  • Open Access

    Escape from thymic deletion and anti-leukemic effects of T cells specific for hematopoietic cell-restricted antigen

    by Ji-Min Ju, Min Ho Jung, Giri Nam, Woojin Kim, Sehwa Oh, Hyun Duk Kim, Joo Young Kim, Jun Chang, Sung Hak Lee, Gyeong Sin Park, et al.

    Whether hematopoietic cell-restricted distribution of antigens affects the degree of thymic negative selection has not been investigated in detail. Here, we show that T cells specific for hematopoietic cell-restricted antigens (HRA) are not completely deleted in the thymus, using the mouse minor histocompatibility antigen H60, the expression of which is restricted to hematopoietic cells. As a result, low avidity T cells escape from thymic deletion. This incomplete thymic deletion occurs to the T cells developing de novo in the thymus of H60-positive recipients in H60-mismatched bone marrow transplantation (BMT). H60-specific thymic deletion escapee CD8+T cells exhibit effector differentiation potentials in the periphery and contribute to graft-versus-leukemia effects in the recipients of H60-mismatched BMT, regressing H60+hematological tumors. These results provide information essential for understanding thymic negative selection and developing a strategy to treat hematological tumors.